Cargando…

In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore

OBJECTIVE: Carbapenem-resistant Acinetobacter baumannii (CR-AB) is an emerging cause of nosocomial infections worldwide. Combination therapy may be the only viable option until new antibiotics become available. The objective of this study is to identify potential antimicrobial combinations against C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Tze-Peng, Tan, Thean-Yen, Lee, Winnie, Sasikala, S., Tan, Thuan-Tong, Hsu, Li-Yang, Kwa, Andrea L.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080872/ https://www.ncbi.nlm.nih.gov/pubmed/21533030 http://dx.doi.org/10.1371/journal.pone.0018485

Ejemplares similares

Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
por: Chang, Kang, et al.
Publicado: (2022)

Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations
por: Teo, Jocelyn, et al.
Publicado: (2015)

Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
por: Lim, Tze-Peng, et al.
Publicado: (2011)

In vitro Comparison of Anti-Biofilm Effects against Carbapenem-Resistant Acinetobacter baumannii: Imipenem, Colistin, Tigecycline, Rifampicin and Combinations
por: Song, Joon Young, et al.
Publicado: (2015)

Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant Acinetobacter baumannii with Polymyxin-Based Combinations
por: Wences, Marisol, et al.
Publicado: (2022)

Tigecycline Versus Colistin in the Treatment of Carbapenem-resistant Acinetobacter baumannii Complex Osteomyelitis
por: Oliveira, Priscila R., et al.
Publicado: (2020)

Polymyxin B, Cefoperazone Sodium-Sulbactam Sodium, and Tigecycline against Multidrug-Resistant Acinetobacter baumannii Pneumonia
por: Hu, Guangxue, et al.
Publicado: (2022)

In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2021)

The Transcriptomic Signature of Tigecycline in Acinetobacter baumannii
por: Li, Liping, et al.
Publicado: (2020)

Resistance mechanisms of tigecycline in Acinetobacter baumannii
por: Sun, Chunli, et al.
Publicado: (2023)

Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline- a case report
por: Guo, Wei, et al.
Publicado: (2018)

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
por: Niu, Tianshui, et al.
Publicado: (2019)

Ω76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistant Acinetobacter baumannii
por: Nagarajan, Deepesh, et al.
Publicado: (2019)

Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems
por: Karakonstantis, Stamatis, et al.
Publicado: (2020)

RapidResa Polymyxin Acinetobacter NP(®) Test for Rapid Detection of Polymyxin Resistance in Acinetobacter baumannii
por: Bouvier, Maxime, et al.
Publicado: (2021)

Risk Factors, Molecular Epidemiology and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study
por: Teo, Jocelyn, et al.
Publicado: (2012)

In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy
por: Mezzatesta, Maria Lina, et al.
Publicado: (2008)

Using an Adenosine Triphosphate Bioluminescent Assay to Determine Effective Antibiotic Combinations against Carbapenem-Resistant Gram Negative Bacteria within 24 Hours
por: Cai, Yiying, et al.
Publicado: (2015)

Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii
por: Nordqvist, H., et al.
Publicado: (2016)

Rifampicin Enhanced Carbapenem Activity with Improved Antibacterial Effects and Eradicates Established Acinetobacter baumannii Biofilms
por: Nwabor, Lois Chinwe, et al.
Publicado: (2023)

Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates
por: Barin, Juliana, et al.
Publicado: (2013)

In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii
por: Zhang, Hui, et al.
Publicado: (2021)

Use of Carbapenems, Polymyxins, and Tigecycline in United States Children’s Hospitals, 2010–2014
por: Chiotos, Kathleen, et al.
Publicado: (2017)

In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
por: Ahmed, Nahid H, et al.
Publicado: (2012)

Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Park, Jae-Min, et al.
Publicado: (2021)

Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae: A Propensity Score-Matched Cohort Study
por: Zha, Lei, et al.
Publicado: (2023)

In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii [Corrigendum]
Publicado: (2021)

Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study
por: Cai, Yiying, et al.
Publicado: (2020)

Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections
por: Lim, Tze-Peng, et al.
Publicado: (2018)

Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae
por: Tian, Yuan, et al.
Publicado: (2021)

Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
por: Zhou, Yvonne Peijun, et al.
Publicado: (2014)

Role of efflux pumps in reduced susceptibility to tigecycline in Acinetobacter baumannii
por: Ardehali, S.H., et al.
Publicado: (2019)

Tigecycline Heteroresistance and Resistance Mechanism in Clinical Isolates of Acinetobacter baumannii
por: Jo, Jeongwoo, et al.
Publicado: (2021)

Sequential intraventricular injection of tigecycline and polymyxin B in the treatment of intracranial Acinetobacter baumannii infection after trauma: a case report and review of the literature
por: Zhong, Li, et al.
Publicado: (2020)

Intrathecal Injection of Tigecycline and Polymyxin B in the Treatment of Extensively Drug-Resistant Intracranial Acinetobacter baumannii Infection: A Case Report and Review of the Literature
por: Li, Ziyu, et al.
Publicado: (2022)

Prevalence and Genetic Characterization of Carbapenem- and Polymyxin-Resistant Acinetobacter baumannii Isolated from a Tertiary Hospital in Terengganu, Malaysia
por: Lean, Soo-Sum, et al.
Publicado: (2014)

Polymyxin Resistance Among XDR ST1 Carbapenem-Resistant Acinetobacter baumannii Clone Expanding in a Teaching Hospital
por: Carrasco, Letícia Dias de Melo, et al.
Publicado: (2021)

A novel decoy strategy for polymyxin resistance in Acinetobacter baumannii
por: Park, Jaeeun, et al.
Publicado: (2021)

Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
por: Lyu, Cheng, et al.
Publicado: (2020)

Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection
por: Shin, Jung Ar, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ft4un6qjillvu93te37draho1n